Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'
Recording and Q&A from webinar 'Recent Progress Towards a Potential Treatment for KCNC-1 Related Disorders'
With enthusiastic engagement from staff, we’ve cultivated a robust H&S culture, ensuring we continuously prioritize the health, safety, and well-being of everyone at Metrion.
IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.
IQ Consortium’s In Vitro Secondary Pharmacology Profiling Working Group article ‘The state of the art in secondary pharmacology and its impact on the safety of new medicines’ recognised as the ‘Most Impactful Safety Pharmacology Publication of the Year’.
'Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays’ (Nucleic Acid Therapeutics) receives ‘2024 Technology Innovation Publication Award’.
Metrion Biosciences provides GLP hERG testing services which crucial for drug discovery and the Investigational New Drug (IND) process. Our focus is on delivering reliable, regulatory-compliant data quickly and cost-effectively.
The hERG gene encodes a potassium ion channel that is essential for repolarizing the cardiac action potential. Inhibition of this channel can prolong the QT interval on an electrocardiogram (ECG), leading to a condition called Torsades de Pointes (TdP), a potentially fatal arrhythmia.
I am currently studying Biomedical Sciences at the University of Manchester. Through my previous years of education, I enjoyed studying biology and engaging in practical experiments, particularly those with clinical relevance, which ultimately guided my degree selection.
The recent ICH E14/S7B Q&As have provided more clarity on the methodologies that should be employed when conducting a GLP hERG to support and IND filing for a novel clinical compound.
My 12 month industrial placement at Metrion Biosciences was a truly remarkable experience that has helped me grow both personally and professionally. Choosing to complete a placement year was a big decision for me which was made 100% worth it!